Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CRSP NASDAQ:DNLI NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.04+7.1%$2.20$0.98▼$4.46$698.94M0.468.12 million shs2.71 million shsCRSPCRISPR Therapeutics$54.71+5.2%$52.52$42.17▼$78.48$5.28B1.741.82 million shs1.08 million shsDNLIDenali Therapeutics$23.83+8.6%$19.86$12.58▼$24.21$3.78B1.031.75 million shs1.07 million shsHALOHalozyme Therapeutics$69.11-0.8%$67.75$51.06▼$82.22$8.20B0.881.76 million shs413,751 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-2.06%+4.40%-5.00%-11.63%+38.69%CRSPCRISPR Therapeutics-1.12%+1.05%+7.46%+9.08%+25.11%DNLIDenali Therapeutics-1.31%+5.48%+17.78%+9.32%+50.00%HALOHalozyme Therapeutics-2.30%-2.57%+3.75%+9.41%+29.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$2.04+7.1%$2.20$0.98▼$4.46$698.94M0.468.12 million shs2.71 million shsCRSPCRISPR Therapeutics$54.71+5.2%$52.52$42.17▼$78.48$5.28B1.741.82 million shs1.08 million shsDNLIDenali Therapeutics$23.83+8.6%$19.86$12.58▼$24.21$3.78B1.031.75 million shs1.07 million shsHALOHalozyme Therapeutics$69.11-0.8%$67.75$51.06▼$82.22$8.20B0.881.76 million shs413,751 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-2.06%+4.40%-5.00%-11.63%+38.69%CRSPCRISPR Therapeutics-1.12%+1.05%+7.46%+9.08%+25.11%DNLIDenali Therapeutics-1.31%+5.48%+17.78%+9.32%+50.00%HALOHalozyme Therapeutics-2.30%-2.57%+3.75%+9.41%+29.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52318.78% UpsideCRSPCRISPR Therapeutics 2.58Moderate Buy$67.7823.89% UpsideDNLIDenali Therapeutics 2.87Moderate Buy$34.2543.75% UpsideHALOHalozyme Therapeutics 2.54Moderate Buy$81.6018.08% UpsideCurrent Analyst Ratings BreakdownLatest HALO, CRSP, ALLO, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026DNLIDenali Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026HALOHalozyme Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/12/2026CRSPCRISPR Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.006/11/2026CRSPCRISPR Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$60.006/3/2026HALOHalozyme Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$90.006/3/2026HALOHalozyme Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACRSPCRISPR Therapeutics$1M5,276.44N/AN/A$20.17 per share2.71DNLIDenali TherapeuticsN/AN/AN/AN/A$6.91 per shareN/AHALOHalozyme Therapeutics$1.40B5.87$4.63 per share14.94$0.42 per share164.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7824.857.530.3023.13%187.91%21.92%8/4/2026 (Estimated)Latest HALO, CRSP, ALLO, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65CRSPCRISPR Therapeutics0.3217.9717.96DNLIDenali Therapeutics0.019.289.28HALOHalozyme Therapeutics8.812.762.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CRSPCRISPR Therapeutics69.20%DNLIDenali Therapeutics92.92%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CRSPCRISPR Therapeutics4.10%DNLIDenali Therapeutics12.50%HALOHalozyme Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.16 million299.60 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.50 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableHALO, CRSP, ALLO, and DNLI HeadlinesRecent News About These CompaniesHalozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price ...June 16 at 3:21 PM | finanznachrichten.deFaithward Advisors LLC Buys Shares of 23,070 Halozyme Therapeutics, Inc. $HALOJune 16 at 7:51 AM | marketbeat.comHalozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029June 15 at 6:00 AM | prnewswire.comEpoch Investment Partners Inc. Reduces Position in Halozyme Therapeutics, Inc. $HALOJune 15 at 3:49 AM | marketbeat.comArrowstreet Capital Limited Partnership Cuts Position in Halozyme Therapeutics, Inc. $HALOJune 15 at 3:09 AM | marketbeat.comKennedy Capital Management LLC Boosts Stock Position in Halozyme Therapeutics, Inc. $HALOJune 14 at 5:48 AM | marketbeat.comWhy Is Halozyme Therapeutics (HALO) Stock Rocketing Higher TodayJune 13, 2026 | theglobeandmail.comRoyal London Asset Management Ltd. Increases Position in Halozyme Therapeutics, Inc. $HALOJune 13, 2026 | marketbeat.comHalozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?June 10, 2026 | zacks.comNatixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALOJune 8, 2026 | marketbeat.comSky Harbour: The Ultimate HALO Investment Taking FlightJune 7, 2026 | seekingalpha.comLos Angeles Capital Management LLC Has $70.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comPrudential PLC Buys 31,077 Shares of Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Trims Position in Halozyme Therapeutics, Inc. $HALOJune 7, 2026 | marketbeat.comHow New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment StoryJune 6, 2026 | finance.yahoo.comTD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALOJune 6, 2026 | marketbeat.comWhy is Halozyme Therapeutics (HALO) stock rocketing higher today?June 5, 2026 | msn.comNorges Bank Buys New Stake in Halozyme Therapeutics, Inc. $HALOJune 5, 2026 | marketbeat.comWhat is Zacks Research's Estimate for HALO Q2 Earnings?June 4, 2026 | marketbeat.comBNP Paribas Financial Markets Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALOJune 4, 2026 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) CEO Sells $690,700.00 in StockJune 3, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Robinhood Wants a Bigger Role in IPOs—Here's Why It MattersBy Leo Miller | June 14, 2026HALO, CRSP, ALLO, and DNLI Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$2.04 +0.14 (+7.11%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CRISPR Therapeutics NASDAQ:CRSP$54.71 +2.69 (+5.17%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Denali Therapeutics NASDAQ:DNLI$23.83 +1.90 (+8.65%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Halozyme Therapeutics NASDAQ:HALO$69.10 -0.54 (-0.77%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Could a Tesla-SpaceX Merger Be Closer Than Investors Think? Flying Under the Radar: Lockheed Martin's $2.8B Stealth Setup Bread’s Comeback Is Real—But Is the Easy Money Gone? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
